MAPT and Alzheimer disease: With three anti-Aβ monoclonal antibodies (Aducanumab, Lecanemab, and Donanemab) approved for the treatment of AD and other antibodies in research (although anti-tau antibodies failed), it is imperative to start treatment as soon as possible, before the full development of the multiple interlinked pathogenic cascades, for optimal therapeutic results [194].